Navigation Links
IDM Pharma Provides Update on Mifamurtide (L-MTP-PE) Regulatory Status Following June Meeting of European Committee for Medicinal Products for Human Use (CHMP)
Date:7/1/2008

As previously announced, the Company is evaluating the Company's research and development programs, including related assets and costs, and strategic alternatives available to the Company.

For more information about the company and its products, visit http://www.idm-pharma.com.

Forward-Looking Statements

This press release includes forward-looking statements that reflect management's current views of future events including the Company's belief that the data from the L-MTP-PE Phase 3 study warrants regulatory approval in Europe and the United States, the Company's plans to address the remaining questions with respect to the MAA for L-MTP-PE during the clock-stop granted by the CHMP, including the Company's plans for completion of data analysis and submission of responses to the CHMP, the Company's expectation that it will attend an oral explanation hearing at the CHMP's September plenary meeting, the expected timing of receipt of a final opinion from the CHMP and receipt of a final regulatory decision regarding the MAA in the European Union, as well as the Company's plans to collect, analyze and submit additional Phase 3 data in an amended NDA for L-MTP-PE, including the expected timing for such amended NDA, and to respond to other matters raised by the FDA and the Company's plans to evaluate strategic alternatives. Actual results may differ materially from the forward-looking statements due to a number of important factors, including, but not limited to, whether the European Commission will follow the final opinion of the CHMP, whether the timing for the final opinion of the CHMP and the regulatory decision in Europe will occur as expected by the Company, the possibility that additional data from the Phase 3 clinical trial of L-MTP-PE and other information in any amendment to the NDA for L-MTP-PE submitted by the Company may not provide adequate support for regulatory approval of L-MTP-PE
'/>"/>

SOURCE IDM Pharma, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Isis Pharmaceuticals Conference Call Notice
2. Peregrine Pharmaceuticals Doses First Patient in Phase II Trial of Bavituximab in Patients With Non-Small Cell Lung Cancer
3. Catalyst Pharmaceutical Partners, Inc. Begins Enrollment for U.S. Phase II Clinical Trial of CPP-109 in Patients with Methamphetamine Addiction
4. XTL Biopharmaceuticals Announces Completion of Patient Randomization Into the Bicifadine Phase 2b Clinical Trial for the Treatment of Diabetic Neuropathic Pain
5. MAP Pharmaceuticals Reports Positive Pharmacological Response Data for Migraine Product Candidate at the American Headache Society Annual Meeting
6. Phase III Data Show Vanda Pharmaceuticals Tasimelteon (VEC-162) Significantly Improves Sleep in Patients with Chronic Insomnia
7. Pharmasset Receives Notice of Allowance
8. Morria Biopharmaceuticals Plc Announces the Initiation of a Phase II Clinical Multi-dose Study of MRX-4 in Allergic Rhinitis
9. CB1400, Patented by Canopus BioPharma, Enters Phase II Clinical Trials for the Prevention of Mucositis in Patients With Cancer of the Head and Neck
10. Alexza Pharmaceuticals to Present AZ-104 Phase 2a Clinical Data at the American Headache Society Annual Scientific Meeting
11. Pharmaxis Concludes Special Protocol Assessment with FDA for Bronchitol Phase 3 Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... OAKS, Calif. , July 30, 2015  Amgen (NASDAQ: ... Hassan , partner and managing director of Warburg Pincus LLC, ... are pleased to welcome Fred Hassan and the ... the Amgen Board," said Robert A. Bradway , chairman ... and commitment to innovation will serve Amgen well." ...
(Date:7/30/2015)... CHAGRIN FALLS, Ohio , July 30, 2015 /PRNewswire/ ... in his OMTEC® 2015 keynote address last month that ... business models in order to gain the efficiencies—and develop ... future. Dr. Barsoum,s comments were preceded by ... Tornier, avid entrepreneur and OMTEC moderator, who stressed that ...
(Date:7/30/2015)... , July 30, 2015  Growth of the ... as they bring former prescription users to the OTC ... Kline forecasts robust Rx-to-OTC switch activity over the ... emerging along with many new brands entering the market ... over the next five years (even those with low ...
Breaking Medicine Technology:Amgen Announces Appointment Of Fred Hassan To Board Of Directors 2Amgen Announces Appointment Of Fred Hassan To Board Of Directors 3Orthopaedic Surgery Reimbursement Shifts to Episode of Care 2Rx-to-OTC Switches -- Game Changers for the U.S. OTC Drugs Market through 2019, Sees Kline 2Rx-to-OTC Switches -- Game Changers for the U.S. OTC Drugs Market through 2019, Sees Kline 3
... 2012  Biomerix Corporation announced today that it has received ... tissue repair mesh, a novel composite mesh intended for ... for the temporary bridging of fascial defects.  This approval ... certification in many other parts of the world that ...
... 2012  Sanofi US today announced that the U. S. ... injunction against a Synvisc-One ® (hylan ... ruling allows for a restricted launch of Seikagaku,s product ... prohibits Seikagaku from selling their product below the current ...
Cached Medicine Technology:Biomerix Receives CE Mark Approval For ASSURE Soft Tissue Repair Mesh 2Sanofi Announces Court Ruling Granting Preliminary Injunction Against Synvisc-One® Competitor Product 2
(Date:7/31/2015)... ... July 31, 2015 , ... Precision Aesthetics is New York’s only Thermage skin ... the first provider of Exilis non-surgical fat reduction in New York. Due to ... a large International clientele. Many patients travel to New York to get their ...
(Date:7/31/2015)... ... July 31, 2015 , ... The 2nd annual Ride to Fight ... Memphis on October 3, 2015. The Ride to Fight On is a cycling fundraiser ... Methodist Healthcare, The West Clinic and The University of Tennessee Health Science Center. A ...
(Date:7/31/2015)... ... July 31, 2015 , ... Jacksonville-based ... its new True North Conference Center. The medical community, social workers, law enforcement, ... may be more aligned in the effort to better understand and combat sex ...
(Date:7/31/2015)... ... July 31, 2015 , ... M3 USA MDLinx.com, source of ... three new Board Exam Courses. , The additions of Gastroenterology, Pulmonology and Allergy/Immunology ... from MDLinx makes preparing for the exam easy and painless. MDLinx offers thousands ...
(Date:7/31/2015)... ... , ... According to an article published July 2 on Healio, ... a consensus on the steps that need to be taken to successfully complete several ... consensus on a series of steps that each surgeon must complete for each procedure. ...
Breaking Medicine News(10 mins):Health News:West Cancer Center Announces 2nd Annual Ride to Fight On 2Health News:West Cancer Center Announces 2nd Annual Ride to Fight On 3Health News:Lakeview Health Links Sex Trafficking and Addiction in Special Jacksonville Educational Workshop 2Health News:Lakeview Health Links Sex Trafficking and Addiction in Special Jacksonville Educational Workshop 3Health News:MDLinx Offers Three New Board Exam Prep Courses - Gastroenterology, Pulmonology and Allergy/Immunology 2Health News:MDLinx Offers Three New Board Exam Prep Courses - Gastroenterology, Pulmonology and Allergy/Immunology 3Health News:Article on Plastic Surgery Consensus Highlights the Duties of Veteran Plastic Surgeons, says Beverly Hills Physicians 2Health News:Article on Plastic Surgery Consensus Highlights the Duties of Veteran Plastic Surgeons, says Beverly Hills Physicians 3
... Radiation Oncology (ASTRO) has released evidence-based guidelines to ... finding that hypofractionated (HF) WBI is effective for ... are published in the International Journal of ... , Studies have shown that WBI following breast ...
... that controls the number of hematopoietic stem cells cells ... In a report in the online Early Edition of ... from Massachusetts General Hospital (MGH) and the Harvard Stem Cell ... of these blood stem cells, an advance that may improve ...
... By Jenifer Goodwin HealthDay Reporter , ... outbreak of whooping cough in decades, public health officials ... those who come into contact with infants, to make ... With the incidence of whooping cough also higher than ...
... DC Delivering timely, open, online access to the ... will significantly increase the return on the public,s investment ... Houghton at the Centre for Strategic Economic Studies at ... on Investment in Open Archiving Publicly Funded Research Outputs," ...
... Yeni H. Ycel, an ophthalmic pathologist at St. Michael,s Hospital, ... the New York Academy of Medicine. Dr. Ycel received ... the human eye that may lead to new treatments for ... assumption that the eye has no lymphatics, the channels responsible ...
... accurately detect and alleviate symptoms of delirium in persons ... the National Institute of Nursing Research. The project, ... seeks to improve nurses, assessment skills and reduce the ... Delirium and dementia have similar symptoms -- decline in ...
Cached Medicine News:Health News:ASTRO publishes whole breast irradiation guidelines 2Health News:MicroRNA molecule increases number of blood stem cells, may help improve cancer treatment 2Health News:Spread of Whooping Cough Raises Concern 2Health News:Spread of Whooping Cough Raises Concern 3Health News:New study examines the economic returns of public access policies 2Health News:Nurses will test method for determining if it's dementia or delirium 2
Reagent Basin, 60mL, 5/Box...
For use with 8 channel pipets....
96 channel Parallel dispenser using Positive Air Displacement Technology...
Manufacturer of the WellPro since 1992, ProGroup previously distributed the instrument through Denley and Labsystems. A direct replacement for the ProPette the WellPro performs serial dilutions in an...
Medicine Products: